Not Yet Recruiting PHASE2 INTERVENTIONAL 2-arm
NCT06648525
Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF ± Lenvatinib As First-line Treatment for Advanced ICC
Adebrelimab Combined with Irinotecan Liposomes, 5-fluorouracil, Calcium Folinate ± Lenvatinib As First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma: a Prospective Clinical Study
Sponsor: Harbin Medical University
Conditions
Intrahepatic Cholangiocarcinoma (Icc)
Updated 1 time since 2024 Last updated: Oct 16, 2024 Started: Oct 31, 2024 Primary completion: Apr 30, 2027 Completion: Apr 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE2 trial investigates Intrahepatic Cholangiocarcinoma (Icc) and is currently actively recruiting participants. Harbin Medical University leads this study, which shows 1 recorded version since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Harbin Medical University
Data source: Harbin Medical University
For direct contact, visit the study record on ClinicalTrials.gov .